Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Stephen E Gitelman"'
Autor:
Carla J. Greenbaum, Elisavet Serti, Katharina Lambert, Lia J. Weiner, Sai Kanaparthi, Sandra Lord, Stephen E. Gitelman, Darrell M. Wilson, Jason L. Gaglia, Kurt J. Griffin, William E. Russell, Philip Raskin, Antoinette Moran, Steven M. Willi, Eva Tsalikian, Linda A. DiMeglio, Kevan C. Herold, Wayne V. Moore, Robin Goland, Mark Harris, Maria E. Craig, Desmond A. Schatz, David A. Baidal, Henry Rodriguez, Kristina M. Utzschneider, Hendrik J. Nel, Carol L. Soppe, Karen D. Boyle, Karen Cerosaletti, Lynette Keyes-Elstein, S. Alice Long, Ranjeny Thomas, James G. McNamara, Jane H. Buckner, Srinath Sanda, for the ITN058AI EXTEND Study Team
Publikováno v:
JCI Insight, Vol 6, Iss 21 (2021)
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in
Externí odkaz:
https://doaj.org/article/083a57294536479793c92cf07ad43e13
Autor:
Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela P. Lares, Ashley S. Leinbach, Michael Lee, Vinh Nguyen, Stanley J. Tamaki, Whitney Tamaki, Courtney M. Tamaki, Morvarid Mehdizadeh, Amy L. Putnam, Matthew H. Spitzer, Chun Jimmie Ye, Qizhi Tang, Jeffrey A. Bluestone
Publikováno v:
JCI Insight, Vol 6, Iss 18 (2021)
BACKGROUND A previous phase I study showed that the infusion of autologous Tregs expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent safety profile. However, the majority of the infused Tregs were undetectable in t
Externí odkaz:
https://doaj.org/article/7153605b428a4670a8f2035fe21e7584
Autor:
Heba M, Ismail, David, Cuthbertson, Stephen E, Gitelman, Jay S, Skyler, Andrea K, Steck, Henry, Rodriguez, Mark, Atkinson, Brandon M, Nathan, Maria J, Redondo, Kevan C, Herold, Carmella, Evans-Molina, Linda A, DiMeglio, Jay, Sosenko
Publikováno v:
Diabetes Care. 45:2264-2270
OBJECTIVE To define the relationship between glucose and C-peptide during the progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS We longitudinally studied glucose and C-peptide response curves (GCRCs), area under curve (AUC) for glucos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81cd59b2211537eda9f617558af1535
https://doi.org/10.2337/dc22-0167
https://doi.org/10.2337/dc22-0167
Autor:
Kevan C. Herold, Anette-Gabriele Ziegler, Darrell M. Wilson, Diane K. Wherrett, John M Wentworth, Jay S. Skyler, Phillip Raskin, Andrew B. Muir, Antoinette M. Moran, Wayne V Moore, Daniel J. Moore, Sandra M. Lord, S. Alice Long, Peter S. Linsley, Ingrid M. Libman, Jeffrey P Krischer, Michael J. Haller, Carla J. Greenbaum, Peter A. Gottlieb, Robin S. Goland, Stephen E. Gitelman, Laura A. Cooney, Mark S. Anderson, Brian N. Bundy, William E. Russell
Objective Previous studies showed that inhibiting lymphocyte costimulation reduces declining beta cell function in individuals newly-diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e612bbc18c514cf7dd93b604e719af2d
https://doi.org/10.2337/figshare.22009586
https://doi.org/10.2337/figshare.22009586
Publikováno v:
Diabetes Technol Ther
Diabetes technology & therapeutics, vol 23, iss 10
Diabetes technology & therapeutics, vol 23, iss 10
Background: The impact of the coronavirus disease-2019 (COVID-19) pandemic on glycemic metrics in children is uncertain. This study evaluates the effect of the shelter-in-place (SIP) mandate on glycemic metrics in youth with type 1 diabetes (T1D) usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3d77b847d3e5102aa0edc3ec801de60
https://doi.org/10.1089/dia.2021.0131
https://doi.org/10.1089/dia.2021.0131
Autor:
Leslie Wilson, Tiffany Kwok, Yanlei Ma, Jenise Wong, Martin Ho, Yelena Ionova, Maureen McGrath, Monica M. Mueller, Stephen E. Gitelman, Telba Irony
Publikováno v:
Transplantation. 106(8)
The advisory panel for US Food and Drug Administration (FDA) recently endorsed pancreatic islet cell transplantation (ICT) therapy for suboptimally controlled type 1 diabetes (T1D), and FDA approval is under consideration. An important part of regula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649cf20ec38d14ae0c238db666cbdd20
https://pubmed.ncbi.nlm.nih.gov/35655355
https://pubmed.ncbi.nlm.nih.gov/35655355
Autor:
LAURA M. JACOBSEN, DAVID D. CUTHBERTSON, MICHAEL J. HALLER, HEBA M. ISMAIL, EMILY K. SIMS, STEPHEN E. GITELMAN, DIANE K. WHERRETT, ANTOINETTE MORAN, MARK A. ATKINSON, ALBERTO PUGLIESE, PETER GOTTLIEB, JAY SOSENKO
Publikováno v:
Diabetes. 71
C-peptide area under the curve (AUC) at ≥1 year, a standard endpoint of recent-onset T1D clinical trials, is derived from a 120-minute mixed meal tolerance test (MMTT) . We analyzed whether composite glucose and C-peptide endpoints, useful in post
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da7ce179f162f2f28573677f4087e30
https://doi.org/10.2337/db22-825-p
https://doi.org/10.2337/db22-825-p
Autor:
Stephen E. Gitelman, Desmond A. Schatz, Mark A. Atkinson, Jasmine A Mack, Laura M. Jacobsen, Brittany S. Bruggeman, Amanda L. Posgai, Peter A. Gottlieb, Michael J. Haller, Andrea Lin, Matthew J. Gurka, Todd M. Brusko, Clayton E. Mathews, Clive Wasserfall
Publikováno v:
Diabetes, vol 70, iss 5
Diabetes
Diabetes
Previously, we demonstrated low-dose anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) immunotherapy preserved C-peptide for two years in a pilot study of subjects with established type 1 diabetes (n=25). Herein, we evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de47f384d13030523c56ef87d2143061
https://doi.org/10.2337/db20-1103
https://doi.org/10.2337/db20-1103
Autor:
Mark A. Atkinson, Desmond A. Schatz, Michael J. Haller, Laura M. Jacobsen, Stephen E. Gitelman, Madison N. Greco, Brian N. Bundy, Todd M. Brusko, Clayton E. Mathews, Kevan C. Herold, Jeffrey P. Krischer
Publikováno v:
Diabetes Technology & Therapeutics
Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6693331fa7e5a2cbce74bb1dac514c
https://doi.org/10.1089/dia.2020.0305
https://doi.org/10.1089/dia.2020.0305
Autor:
Kevan C. Herold, Peter A. Gottlieb, Louis H. Philipson, James Dziura, David A. Baidal, Ruth S. Weinstock, Jason L. Gaglia, Rodica Pop-Busui, Jennifer B. Marks, Stephen E. Gitelman, Jesse Reynolds
Publikováno v:
Diabetes, obesity & metabolism, vol 22, iss 11
Diabetes Obes Metab
Diabetes Obes Metab
AIMS: To test whether a long-acting GLP-1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c923f3404bac8533ff93ea3c5316af
https://doi.org/10.1111/dom.14121
https://doi.org/10.1111/dom.14121